BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33811727)

  • 1. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
    Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
    Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
    Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
    World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
    Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
    Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
    Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
    Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer.
    Advani SM; Shi Q; Overman MJ; Loree JM; Lam M; Morris V; Shureiqi I; Kee B; Dasari A; Vilar E; Sarshekeh AM; Lin HK; Manuel S; Hamilton S; Raghav K; Maru D; Kopetz S; Wang XS
    Clin Colorectal Cancer; 2020 Mar; 19(1):48-56.e2. PubMed ID: 32008976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
    Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
    Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
    Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
    Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.